Positive phase III data from PSOARING 1 and PSOARING 2 trials reported for tapinarof cream in treatment of plaque psoriasis

At week 12, 35.4% & 40.2% of patients on this topical aryl hydrocarbon receptor modulating agent in PSOARING 1 & PSOARING 2 respectively achieved primary endpoint of PGA score of clear (0) or almost clear (1) with minimum 2-grade improvement vs 6.0% & 6.3 with vehicle (p<0.0001).


Biospace Inc.